Erlotinib in lung cancer

N Engl J Med. 2005 Oct 20;353(16):1739-41; author reply 1739-41. doi: 10.1056/NEJMc052173.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • ErbB Receptors / antagonists & inhibitors
  • Erlotinib Hydrochloride
  • Humans
  • Lung Neoplasms / drug therapy*
  • Placebos*
  • Protein Kinase Inhibitors / therapeutic use*
  • Quinazolines / therapeutic use*
  • Randomized Controlled Trials as Topic / ethics
  • Survival Rate

Substances

  • Placebos
  • Protein Kinase Inhibitors
  • Quinazolines
  • Erlotinib Hydrochloride
  • ErbB Receptors